|Bid||13.50 x 900|
|Ask||14.02 x 800|
|Day's Range||13.73 - 14.84|
|52 Week Range||11.70 - 49.23|
|Beta (5Y Monthly)||2.74|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 07, 2022 - Nov 11, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||49.91|
Subscribe to Yahoo Finance Plus to view Fair Value for ARCT
SAN DIEGO, September 27, 2022--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a global, late-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that the Company will participate in the following investor conferences.
With several worrying developments domestically and internationally, many investors chose to rush for the exits, though a brave few may have opportunities in small-cap stocks to buy on the dip. Tethered to small-capitalization companies, these market ideas don’t always grab the spotlight. But when they do, their relatively diminutive profiles occasionally enable massive profitability. Effectively, small-cap stocks to buy are the equivalent of carrying small objects uphill rather than large ones.
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...